<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: We have previously reported that mivazerol, a alpha(2)-<z:chebi fb="4" ids="48705">agonist</z:chebi>, possibly provides neuroprotection against transient forebrain <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> in rats </plain></SENT>
<SENT sid="1" pm="."><plain>This study was designed to investigate the ability of mivazerol to attenuate <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e>-induced increase in striatal <z:chebi fb="1" ids="18357,33569">norepinephrine</z:chebi> concentration after transient forebrain <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> in rats </plain></SENT>
<SENT sid="2" pm="."><plain>METHODS: Male Sprague-Dawley rats, anesthetized with <z:chebi fb="2" ids="5615">halothane</z:chebi>, were assigned to one of three groups (n=10 each); control (C, <z:mpath ids='MPATH_458'>normal</z:mpath> saline 1 ml/kg), mivazerol 20 microg/kg (M20), and 40 microg/kg (M40) groups </plain></SENT>
<SENT sid="3" pm="."><plain>Monitored variables included temporal muscle temperature (maintained at 37.5+/-0.1 degrees C), electroencephalogram, systolic/diastolic blood pressure, heart rate, arterial blood gases, and blood <z:chebi fb="105" ids="17234">glucose</z:chebi> concentrations </plain></SENT>
<SENT sid="4" pm="."><plain>Thirty minutes after subcutaneous drug administration, forebrain <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> was induced with hemorrhagic <z:hpo ids='HP_0002615'>hypotension</z:hpo> (systolic arterial pressure: 40-50 mmHg) and bilateral carotid <z:mp ids='MP_0006134'>artery occlusion</z:mp> for 10 min, and then the brain was reperfused </plain></SENT>
<SENT sid="5" pm="."><plain><z:chebi fb="1" ids="18357,33569">Norepinephrine</z:chebi> concentration in the interstitial fluids in the striatum was analyzed using in vivo microdialysis in combination with high-performance liquid chromatography </plain></SENT>
<SENT sid="6" pm="."><plain>RESULTS: <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">Ischemia</z:e> resulted in a prompt increase in <z:chebi fb="1" ids="18357,33569">norepinephrine</z:chebi> concentrations in the striatum in <z:hpo ids='HP_0000001'>all</z:hpo> groups </plain></SENT>
<SENT sid="7" pm="."><plain>However, there were no significant differences in <z:chebi fb="1" ids="18357,33569">norepinephrine</z:chebi> concentrations in the striatum between the three groups at any period </plain></SENT>
<SENT sid="8" pm="."><plain>CONCLUSIONS: Our results indicate that mivazerol did not attenuate <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e>-induced increase in striatal <z:chebi fb="1" ids="18357,33569">norepinephrine</z:chebi> concentration </plain></SENT>
<SENT sid="9" pm="."><plain>This suggests that the possible neuroprotective property of mivazerol is not related to inhibition of <z:chebi fb="1" ids="18357,33569">norepinephrine</z:chebi> release in the brain </plain></SENT>
</text></document>